

Tetyana A Pertseva

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8843525/publications.pdf>

Version: 2024-02-01

32
papers

91
citations

2258059

3
h-index

2550090

3
g-index

32
all docs

32
docs citations

32
times ranked

76
citing authors

#	ARTICLE	IF	CITATIONS
1	Influence the phosphatidylcholine treatment program on surfactant protein D levels in hypertensive patients with community-acquired pneumonia. , 2018, , .		0
2	Is it connection between systemic inflammation and risk of thrombotic disorders (by Padua scale) in hospitalized patients with community-acquired pneumonia (CAP)? . , 2018, , .		0
3	Thrombotic disorders (blood coagulation test and Padua Prediction Score for risk of lung) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50		0
4	HEALTH RELATED QUALITY OF LIFE (HRQoL) AMONG PATIENTS WITH NON CYSTIC FIBROSIS BROCHIECTASIS (BE) IN STABLE PHASE. , 2018, , .		0
5	Levels of serum amyloid A (SAA) and C-reactive protein (CRP) in stable COPD patients and its relationship with disease severity. , 2017, , .		0
6	Comparison of severity of clinical, functional signs of COPD with the frequency and severity of mental disorders. , 2017, , .		0
7	Effects of nebivolol and ivabradine on myocardial ischemia in patients (pts) with COPD and stable angina during 24-hour ambulatory Holter ECG monitoring. , 2017, , .		0
8	Adherence to ICS in pregnant with infectious exacerbations of asthma (IEA). , 2017, , .		0
9	Pneumonias in immunocompromised patients: improvement of treatment using the immunomodulator. ScienceRise: Medical Science, 2017, .	0.0	0
10	Influence of tobacco-smoking on serum level of transforming growth factor (TGF) beta 1 in COPD patients. , 2017, , .		1
11	Long-Term Fluticasone Propionate/Formoterol Fumarate Combination Therapy Is Associated with a Low Incidence of Severe Asthma Exacerbations. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2016, 29, 346-361.	1.4	24
12	Can procalcitonin (PCT) be an indicator of viral severe community-acquired pneumonia (CAP) based on epidemics of influenza H₁N₁ in season 2015-2016?. , 2016, , .		0
13	Plasma surfactant protein-D (SPD) concentration and severity of airflow limitation in COPD patients (pts). , 2016, , .		0
14	Can procalcitonin or C-reactive protein predict suppurative lung complications and ARDS at severe community-acquired pneumonia (CAP)? . , 2016, , .		0
15	Changes in levels of inflammatory markers (procalcitonin, C-reactive protein) in pregnant with community-acquired pneumonia (CAP). , 2016, , .		0
16	Whether there are pharmaco-economic and other advantages of using procalcitonin-guide antibacterial treatment in patients with severe community-acquired pneumonia in developing countries?. , 2015, , .		0
17	Role of matrix metalloproteinase in predicting of COPD stability. , 2015, , .		0
18	Features of systemic inflammation in patients with severe community-acquired (CAP) pneumonia of different etiology in HIV-infected patients. , 2015, , .		0

#	ARTICLE	IF	CITATIONS
19	The relationship between dyspnea and detection of depression in COPD patients (pts). , 2015, , .		0
20	Proteinase-inhibitor system state in patients with COPD. , 2015, , .		0
21	Surfactant protein D (SPD) like marker of effectiveness in patients (pts) with acute exacerbations (AE) of COPD ofphosphatidylcholine treatment outcomes. , 2015, , .		0
22	Vascular-platelet hemostasis parameters in the stable phase and in acute exacerbation (AE) of COPD. , 2015, , .		0
23	Could procalcitonin (PCT) be a marker of effectiveness of antibiotic treatment (ABT) in pregnant with not severe community-acquired pneumonia (CAP)?. , 2015, , .		0
24	Matrix metalloproteinase, hyaluronic acid and C-reactive protein: Are they really markers of lung obstruction at COPD but not cardiovascular comorbidity?. , 2015, , .		0
25	Myocardial ischemia in patients (pts) with COPD and stable angina during 24-hour ambulatory Holter ECG monitoring. , 2015, , .		0
26	COPD: Inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA) combination and oxygen saturation (OS) in patients (pts) with different plasma surfactant protein D (SP-D) level. , 2015, , .		0
27	What is the best biomarker of COPD stability?. , 2015, , .		0
28	Surfactant protein D (SPD) like marker of effectiveness ofphosphatidylcholine treatment outcomes in patients (pts) with community acquired pneumonia (CAP). , 2015, , .		0
29	Peculiarities of climacteric syndrome in women with bronchial asthma, developed in the perimenopausal period, correction of these disorders. , 2015, , .		0
30	"Many-armedâ€•CD4: Why it is necessary to count blood CD4 at patient with severe community-acquired pneumonia (CAP)?. , 2015, , .		0
31	Superiority of fluticasone propionate/formoterol fumarate versus fluticasone propionate alone in patients with moderate-to-severe asthma: a randomised controlled trial. Current Medical Research and Opinion, 2013, 29, 1357-1369.	1.9	21
32	Efficacy and safety of fluticasone/formoterol combination therapy in patients with moderate-to-severe asthma. Respiratory Medicine, 2013, 107, 180-195.	2.9	45